 NEW YORK, Nov. 3, 2020 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus CLE, a chronic... 